BC
Boxer Capital of the Tavistock Group
Founded 2005
Boxer Capital, a venture capital firm of the Tavistock Group, focuses on identifying and investing in new therapeutics that improve patient care and outcomes. Their strategy involves investing across the entire drug development lifecycle, from early-stage preclinical discovery to late-stage clinical and commercial-stage companies, primarily within the biotechnology and life sciences sectors, with a strong emphasis on targeted oncology.
100% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-c (75% of deals). Average disclosed round size is $89.9M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
$5.3B
Top Stage
Series C
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Black Diamond Therapeutics | Series C | $85M | Dec 2019 |
 Encoded Therapeutics, Inc. | Series C | $104M | Jun 2019 |
 IDEAYA Biosciences | Series B | $94M | Mar 2018 |
 Codiak BioSciences Inc. | Series C | $76.5M | Nov 2017 |
Top Co-Investors
Alexandria Venture Investments3 shared
ARCH Venture Partners2 shared
Casdin Capital2 shared
Perceptive Advisors2 shared
Roche Venture Fund2 shared
Flagship Pioneering1 shared
Alaska Permanent Fund1 shared
Qatar Investment Authority1 shared
Canaan Partners1 shared
GV (Google Ventures)1 shared
WuXi Healthcare Ventures1 shared
Menlo Ventures1 shared
Matrix Partners1 shared
Venrock1 shared
Illumina Ventures1 shared
Altitude Life Science Ventures1 shared
RTW Investments1 shared
Wellington Management1 shared
NEA (New Enterprise Associates)1 shared
Deerfield1 shared
Last updated: 16 April 2026